Rossari Biotech Limited (ROSSARI) fair value: what the stock is really worth
We calculate from audited financials what Rossari Biotech Limited is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Rossari Biotech Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ₹378.60 – ₹1,250 · fair‑value band ₹329.92 – ₹572.43 · the ₹446.15 price screens below the ₹457.94 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions.
Show more
Rossari Biotech Limited manufactures and sells specialty chemicals in India and internationally. It offers soap and detergents; inks, paints, and coatings; ceramics and tiles; pulp and papers; cement; performance additives; and water treatment solutions. The company also provides textile specialty chemicals, such as cotton, polyester, acrylic, wool, silk, nylon, functional finishes, denim, printing, and sustainable solutions; and pet grooming products, which include natural pet shampoos, powders, deodorants, sprays, creams, and floor washing liquids under the Lozalo, Hunger Fills, and Sniffy brand names. In addition, it offers poultry nutrition products comprising vitamin-mineral formulations, toxin binders, individual and cocktail enzymes, liquid nutraceuticals, and supplements or herbal preparations. The company was formerly known as Rossari Labtech and changed its name to Rossari Biotech Limited in December 2003. Rossari Biotech Limited was founded in 1997 and is based in Mumbai, India.
Stock analysis
Rossari Biotech Limited (ROSSARI) currently trades at ₹446.15, while our model-based Fair Value estimate is ₹457.94, implying the stock looks roughly 2.6% fairly valued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of ₹735.16 per share, and 10 of the 16 models we run sit above the ₹446.15 price.
Bear case: the Asset-Based group reads lowest at ₹161.28, and 6 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: ₹329.92 (bear) to ₹572.43 (bull), the price of ₹446.15 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 44/100 (below-average quality), in the Basic Materials sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Rossari Biotech Limited reported revenue of ₹24.0B in FY2026 versus ₹14.8B in FY2022, a compound +12.7%/yr. Reported net income was ₹1.5B in FY2026, compounding +11.2%/yr from FY2022.
Key figures
Market cap ₹29.0B (≈ $304M) · P/E ratio 16.6 · P/S ratio 1.03 · EPS (TTM) ₹26.93 · Dividend yield 0.1% · Net margin 6.2% · Return on equity 11.9% · Return on assets (EBIT) 14.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 42% below its 52-week high and 19% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −47% fair-value upside, at 3%, ROSSARI screens cheaper than that median.
Fair Value models
Bear ₹329.92Fair Value ₹457.94Bull ₹572.43
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2026 figures (about 5 months old). Earnings retained since then (₹12.32 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.58/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+15.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+13.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+27.6%
Revenue growth 9 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+29.4%
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
+11.8%
Earnings growth per share plus dividend.
Earnings per share, growth per year+11.7%
Dividend (yield on the price)0.1%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12% vs 25%, slowing
Profit margin 2021 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.14% → 9%
Compare Rossari Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Specialty Chemicals · 706 stocks
Beats the industry median on 9/13 measures
Overall it ranks above its industry peers.
Valuation
Quality Score44 · Below median
Fair Value upside−1% · Above median
Profitability
Return on equity (TTM)12% · Top 25%
Return on assets6% · Top 25%
Net margin (TTM)6% · Above median
Operating margin (TTM)5% · Below median
Growth and dividend
Revenue growth18% · Top 25%
Dividend yield (TTM)0.1% · Bottom 25%
Balance sheet
Debt / equity0.07× · Below median
Valuation Multiplesvs Specialty Chemicals median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Rossari Biotech Limited (ROSSARI) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ₹457.94 versus a price of ₹446.15, about +3% upside (fairly valued).
What is the fair value of ROSSARI?
Our model-based fair value for Rossari Biotech Limited is ₹457.94 (as of Sep 13, 2026), built from audited fundamentals. The current price: ₹446.15.
What is the quality score of ROSSARI?
Rossari Biotech Limited has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Rossari Biotech Limited (ROSSARI)?
Our model-based price target is the fair value of ₹457.94 (as of Sep 13, 2026) from 16 valuation models. Cautious scenario ₹329.92, optimistic scenario ₹572.43. It is a calculation from audited fundamentals, not an analyst target.
What is the Rossari Biotech Limited stock forecast for 2026?
Our models put fair value at ₹457.94, about +3% upside versus a price of ₹446.15 (fairly valued). Cautious scenario ₹329.92, optimistic scenario ₹572.43. The calculation is refreshed regularly with new filings.
What is the revenue of Rossari Biotech Limited (ROSSARI)?
Rossari Biotech Limited reported trailing-twelve-month revenue of about ₹24.0B (latest available figure, as of Sep 13, 2026).
Does Rossari Biotech Limited pay a dividend?
Rossari Biotech Limited currently shows a dividend yield of about 0.10% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Rossari Biotech Limited (ROSSARI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Rossari Biotech Limited it is ₹457.94 per share (as of Sep 13, 2026), against a price of ₹446.15. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Rossari Biotech Limited stock overvalued or undervalued in 2026?
As of Sep 13, 2026, ROSSARI trades below its calculated fair value: price ₹446.15, fair value ₹457.94, a gap of about +3% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ROSSARI?
No. The price is what the market pays today (₹446.15); the fair value is what the company's own numbers justify (₹457.94). For Rossari Biotech Limited the two are ₹11.79 per share apart. That gap is exactly why we show both numbers side by side.
How much is Rossari Biotech Limited worth?
The market values Rossari Biotech Limited at about ₹29.0B (market capitalisation, as of Sep 13, 2026). Per share that is ₹446.15; our models calculate a fair value of ₹457.94 per share.
What do the bullish and bearish scenarios say about ROSSARI?
Our models span a range for Rossari Biotech Limited: cautious scenario ₹329.92, base ₹457.94, optimistic ₹572.43 per share (as of Sep 13, 2026, price ₹446.15). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of ROSSARI?
Rossari Biotech Limited trades at a price-to-earnings ratio of 16.6 (as of Sep 13, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹457.94 is built from several models across several years. Other multiples: P/B 2.2, P/S 1.2, EV/EBITDA 11.1.
How solid is the balance sheet of Rossari Biotech Limited (ROSSARI)?
Balance-sheet figures for Rossari Biotech Limited (as of Sep 13, 2026): return on equity 11.9%, debt of 0.07 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is ROSSARI from its 52-week high?
Rossari Biotech Limited trades at ₹446.15, about 42% below its 52-week high of ₹766.00 and 19% above the low of ₹375.00 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ₹457.94 is for.
Which stocks are comparable to Rossari Biotech Limited?
From the same area (Basic Materials) we also value Linde plc, The Sherwin-Williams Company, Ecolab Inc, Air Products and Chemicals, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Rossari Biotech Limited stock attractive at the current price?
The data as of Sep 13, 2026: price ₹446.15, calculated fair value ₹457.94 (+3%), Quality Score 44/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of ROSSARI calculated?
We run Rossari Biotech Limited through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹457.94, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Rossari Biotech Limited currently trades 3 % below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Rossari Biotech Limited right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. The price sits in the lower half of our model range, the side with the larger margin of safety. The data supports the verdict: every model runs on fully documented inputs.
Key figures of Rossari Biotech Limited
How large is the market capitalisation of Rossari Biotech Limited (ROSSARI)?
The market capitalisation of Rossari Biotech Limited is ₹29.0B (≈ $304M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Rossari Biotech Limited (ROSSARI)?
The price-to-sales ratio of Rossari Biotech Limited is 1.03 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Rossari Biotech Limited (ROSSARI)?
Earnings per share at Rossari Biotech Limited are ₹26.93 (price ÷ EPS = P/E 16.6). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Rossari Biotech Limited (ROSSARI)?
The dividend yield of Rossari Biotech Limited is 0.1% (payout 1.6%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Rossari Biotech Limited (ROSSARI)?
The net margin of Rossari Biotech Limited is 6.2% (fiscal year 2026). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Rossari Biotech Limited (ROSSARI)?
The return on equity (ROE) of Rossari Biotech Limited is 11.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Rossari Biotech Limited (ROSSARI)?
On an EBIT basis the return on assets of Rossari Biotech Limited is 14.0% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Rossari Biotech Limited (ROSSARI)?
The operating margin of Rossari Biotech Limited is 5.4% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Rossari Biotech Limited (ROSSARI)?
Revenue at Rossari Biotech Limited is growing +18.2% versus a year earlier (3y avg +13.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Rossari Biotech Limited (ROSSARI)?
Earnings per share at Rossari Biotech Limited are growing +33.5% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Rossari Biotech Limited (ROSSARI) generate?
The free cash flow of Rossari Biotech Limited is −₹2.2B (fiscal year 2026). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Rossari Biotech Limited (ROSSARI) carry?
The net debt of Rossari Biotech Limited is ₹3.4B (fiscal year 2026). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Rossari Biotech Limited in the live analysis
One click puts Rossari Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
